DNA Damage Repair in Glioblastoma: A Novel Approach to Combat Drug Resistance
Cell Proliferation · 2025-06 · 58 (6)
DOI: 10.1111/cpr.13815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 27.01.2025. Verfasst von Ludovica Gaiaschi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Biotechnology, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Glioblastoma, Drug Resistance, Neoplasm, DNA Damage, DNA Repair. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Pavia with Fondi Ricerca Giovani, Immuno-HUB_DSM50, T4-CN-02, Immunotherapy: Treatment and Prevention of Infectious and Tumour Diseases.
Abstract (Originalsprache)
Due to the lack of effective therapeutic approach, glioblastoma (GBM) remains one of the most malignant brain tumour. By in vitro investigations on primary GBM stem cells, we highlighted one of the underlying mechanisms of drug resistance to alkylating agents, the DNA damage responses. Here, flow cytometric analysis and viability and repopulation assays were used to assess the long‐term cytotoxic effect induced by the administration of a fourth‐generation platinum prodrug, the ( OC ‐6‐44)‐acetatodiamminedichlorido(2‐(2‐propynyl)octanoato) platinum(IV) named Pt(IV)Ac‐POA, in comparison to the most widely used Cisplatin. The immunofluorescence studies revealed changing pathways involved in the DNA damage response mechanisms in response to the two chemotherapies, suggesting in particular the role of Poly (ADP‐Ribose) polymerases in the onset of resistance to Cisplatin‐induced cytotoxicity. Thus, this research provides a proof of concept for how the use of a prodrug which allows the co‐administration of Cisplatin and an Histone DeACetylase inhibitors, could suppress DNA repair mechanisms, suggesting a novel effective approach in GBM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
- Department of Sciences and Technological Innovation (DiSIT), University of Piemonte Orientale "A. Avogadro", Alessandria, Italy.
- Department of Sustainable Development and Ecological Transition, University of Piemonte Orientale, Vercelli, Italy.
- Unit of Immunotherapy of Brain Tumors, Fondazione IRCCS Istituto Neurologico "C. Besta", Milan, Italy.
ORCID-Profile: Ludovica Gaiaschi
Förderung
- University of Pavia with Fondi Ricerca Giovani
- Immuno-HUB_DSM50, T4-CN-02, Immunotherapy: Treatment and Prevention of Infectious and Tumour Diseases
Zitieren
APA
Gaiaschi, L., Casali, C., Stabile, A., D'Amico, S., Ravera, M., Gabano, E., Galluzzo, A., Favaron, C., Gola, F., De Luca, F., Pellegatta, S., & Bottone, M. G. (2025). DNA Damage Repair in Glioblastoma: A Novel Approach to Combat Drug Resistance. Cell Proliferation, 58(6). https://doi.org/10.1111/cpr.13815
Vancouver
Gaiaschi L, Casali C, Stabile A, D'Amico S, Ravera M, Gabano E, et al. DNA Damage Repair in Glioblastoma: A Novel Approach to Combat Drug Resistance. Cell Proliferation. 2025;58(6). doi:10.1111/cpr.13815
BibTeX
@article{Gaiaschi2025,
author = {Gaiaschi, Ludovica and Casali, Claudio and Stabile, Andrea and D'Amico, Sharon and Ravera, Mauro and Gabano, Elisabetta and Galluzzo, Andrea and Favaron, Cristina and Gola, Federica and De Luca, Fabrizio and Pellegatta, Serena and Bottone, Maria Grazia},
title = {DNA Damage Repair in Glioblastoma: A Novel Approach to Combat Drug Resistance},
journal = {Cell Proliferation},
year = {2025},
volume = {58},
number = {6},
doi = {10.1111/cpr.13815}
}
EUVIMED